Literature DB >> 7572713

Effective homocysteine metabolism may protect South African blacks against coronary heart disease.

J B Ubbink1, W J Vermaak, R Delport, A van der Merwe, P J Becker, H Potgieter.   

Abstract

L-Methionine (0.1 g/kg body wt) was administered to young white [n = 18; mean (+/- SD) age 20.0 +/- 1.0 y] and black [n = 12; mean (+/- SD) age 22.0 +/- 1.3 y] volunteers who had a similar lifestyle and who did not differ significantly from each other with respect to plasma folate or vitamin B-12 concentrations. Blacks, however, had significantly lower plasma pyridoxal-5'-phosphate concentrations compared with whites (P < 0.001). Fasting plasma homocysteine concentrations in blacks and whites were not significantly different. The mean (+/- SD) maximum increase in plasma homocysteine concentration measured after methionine loading was significantly lower (P < 0.01) in blacks (11.0 +/- 3.6 mumol/L) than in whites (18.0 +/- 6.2 mumol/L). Six weeks of vitamin supplementation (1.0 mg folic acid, 400 micrograms vitamin B-12, and 10 mg pyridoxine/d) reduced the mean (+/- SD) fasting plasma homocysteine concentration from 9.6 +/- 3.5 to 7.2 +/- 1.6 mumol/L in whites (P < 0.05) and from 8.4 +/- 2.4 to 5.6 +/- 1.4 mumol/L in blacks (P < 0.01). The mean (+/- SD) maximum increase in plasma homocysteine concentration after methionine loading declined from 18.0 +/- 6.2 to 11.1 +/- 2.3 mumol/L (P < 0.01) in whites, but vitamin supplementation did not have a significant effect on the methionine-load test in black volunteers. A significant race-by-time interaction shows that blacks metabolized homocysteine more effectively than did whites, which may partly explain their relative resistance against coronary heart disease despite a high prevalence of obesity, hypertension, and smoking.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7572713     DOI: 10.1093/ajcn/62.4.802

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  9 in total

Review 1.  Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inaemia.

Authors:  Brahmajee K Nallamothu; A Mark Fendrick; Gilbert S Omenn
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

2.  The effect of a subnormal vitamin B-6 status on homocysteine metabolism.

Authors:  J B Ubbink; A van der Merwe; R Delport; R H Allen; S P Stabler; R Riezler; W J Vermaak
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 3.  Assessment of homocysteine status.

Authors:  H Refsum; T Fiskerstrand; A B Guttormsen; P M Ueland
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

Review 4.  The role of vitamins in the pathogenesis and treatment of hyperhomocyst(e)inaemia.

Authors:  J B Ubbink
Journal:  J Inherit Metab Dis       Date:  1997-06       Impact factor: 4.982

Review 5.  Should all elderly people receive folate supplements?

Authors:  J B Ubbink
Journal:  Drugs Aging       Date:  1998-12       Impact factor: 3.923

6.  Elevated homocysteine level and folate deficiency associated with increased overall risk of carcinogenesis: meta-analysis of 83 case-control studies involving 35,758 individuals.

Authors:  Donghong Zhang; Xuemei Wen; Wei Wu; Ye Guo; Wei Cui
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

7.  Relationship between plasma homocysteine and blood pressure in hypertensive Northern-Nigerians.

Authors:  Obiageli Uzoamaka Onyemelukwe; Bilkisu Bello Maiha
Journal:  Afr Health Sci       Date:  2020-03       Impact factor: 0.927

8.  Off pump coronary artery bypass surgery in a Nigerian teaching hospital.

Authors:  Michael Sanusi; Bode Falase; Salisu Ismail; Adetinuwe Majekodunmi; Adeyemi Johnson; Ifeoluwa Ajose; David Oke
Journal:  Pan Afr Med J       Date:  2013-03-28

9.  Different lipid profiles according to ethnicity in the Heart of Soweto study cohort of de novo presentations of heart disease.

Authors:  Karen Sliwa; Jasmine G Lyons; Melinda J Carrington; Sandrine Lecour; A David Marais; Frederick J Raal; Simon Stewart
Journal:  Cardiovasc J Afr       Date:  2012-08       Impact factor: 1.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.